Molecular & Cellular Toxicology

The Korean Society of Toxicogenomics and Toxicoproteomics (대한독성유전 단백체학회)
권호 표지

Increased Expression of Histone Deacetylase 2 is Found in Human Hepatocellular Carcinoma

  • Noh, Ji-Heon (Lab of Pathology, College of Medicine The Catholic University of Korea) ;
  • Eun, Jung-Woo (Lab of Pathology, College of Medicine The Catholic University of Korea) ;
  • Ryu, So-Yeon (Lab of Pathology, College of Medicine The Catholic University of Korea) ;
  • Jeong, Kwang-Wha (Lab of Pathology, College of Medicine The Catholic University of Korea) ;
  • Kim, Jung-Kyu (Lab of Pathology, College of Medicine The Catholic University of Korea) ;
  • Lee, Sug-Hyung (Lab of Pathology, College of Medicine The Catholic University of Korea) ;
  • Park, Won-Sang (Lab of Pathology, College of Medicine The Catholic University of Korea) ;
  • Yoo, Nam-Jin (Lab of Pathology, College of Medicine The Catholic University of Korea) ;
  • Lee, Jung-Young (Lab of Pathology, College of Medicine The Catholic University of Korea) ;
  • Nam, Suk-Woo (Lab of Pathology, College of Medicine The Catholic University of Korea)
  • Published : 2006.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Accumulated evidences have established that aberrant regulation of histone deacetylases (HDACs) is one of major causes for development of human malignancies. Mammalian HDACs can be divided into three subclasses consisting of 11 homologous of HDACs and 7 of sirtuins, but little is known about HDAC2 causes for carcinogenesis in solid tumors. Here, in order to investigate the roles of HDAC2 in carcinogenesis of liver cancer progression, we analyzed the expression of HDAC2 in 62 human hepatocellular carcinomas by utilizing Immunohistochemistry. Moderate to strong expression of HDAC2 was found in 54 (87%) out of total 62 tumors. The majority of positive tumors were detected in nucleous, but normal hepatocytes did not express of HDAC2 or showed weak positive staining. Interestingly, we were also noted that HDAC2 expression was appeared to be associated with aggressiveness of the tumors by the fact that HDAC2 expression was observed with significances in high grade tumors (Edmonson grade II, III). Taken together, we found the aberrant expression of HDAC2 in hepatocellular carcinomas, and this suggests that HDAC2 may play an important role in the development of liver cancer.

Keywords

References

  1. Parkin, D.M., Pisani, P. & Ferlay, J. Global cancer statistics. CA Cancer J Clin. 49, 33-64 (1999). https://doi.org/10.3322/canjclin.49.1.33
  2. Schafer, D.F. & Sorrell, M.F. Hepatocellular carcinoma. Lancet 353, 1253-1257 (1999) https://doi.org/10.1016/S0140-6736(98)09148-X
  3. de La Coste, A. et al. Somatic mutations of the betacatenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 95, 8847-8851 (1998)
  4. Satoh, S. et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet. 24, 245-250 (2000) https://doi.org/10.1038/73448
  5. Fearon, E.R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990) https://doi.org/10.1016/0092-8674(90)90186-I
  6. Kinzler, K.W. & Vogelstein, B. Life (and death) in a malignant tumour. Nature 379, 19-20 (1996) https://doi.org/10.1038/379019a0
  7. Pang, A., Ng, I.O., Fan, S.T. & Kwong, Y.L. Clinicopathologic significance of genetic alterations in hepatocellular carcinoma. Cancer Genet Cytogenet 146, 8-15 (2003) https://doi.org/10.1016/S0165-4608(03)00103-1
  8. Marks, P.A., Richon, V.M. & Rifkind, R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 92, 1210-1216 (2000) https://doi.org/10.1093/jnci/92.15.1210
  9. Weidle, U.H. & Grossmann, A. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res. 20, 1471-1485 (2000)
  10. Frye, R.A. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun. 273, 793-798 (2000) https://doi.org/10.1006/bbrc.2000.3000
  11. Imai, S., Armstrong, C.M., Kaeberlein, M. & Guarente, L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403, 795-800 (2000) https://doi.org/10.1038/35001622
  12. Yang, W.M. et al. Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J Biol Chem. 272, 28001-28007 (1997) https://doi.org/10.1074/jbc.272.44.28001
  13. Ballestar, E. & Esteller, M. The impact of chromatin in human cancer: linking DNA methylation to gene silencing. Carcinogenesis 23, 1103-1109 (2002) https://doi.org/10.1093/carcin/23.7.1103
  14. Gui, C.Y. et al. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter- associated proteins, including HDAC1. Proc Natl Acad Sci USA 101, 1241-1246 Epub 2004 Jan 20 (2004)
  15. Villar-Garea, A. & Esteller, M. Histone deacetylase inhibitors: Understanding a new wave of anticancer agents. Int J Cancer 112, 171-178 (2004) https://doi.org/10.1002/ijc.20372
  16. Zhu, P. et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5, 455-463(2004) https://doi.org/10.1016/S1535-6108(04)00114-X
  17. Clements, W.M. et al. Beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res. 62, 3503-3506 (2002)
  18. Park, W.S. et al. Somatic mutations of the trefoil factor family 1 gene in gastric cancer. Gastroenterology 119, 691-698 (2000) https://doi.org/10.1053/gast.2000.16483
  19. Park, W.S. et al. Inactivating mutations of the caspase- 10 gene in gastric cancer. Oncogene 21, 2919- 2925 (2002) https://doi.org/10.1038/sj.onc.1205394